Small Cell Lung Carcinoma: all 1,234 studies
Page 9 of 13. Open to participants first (350), then studies with results posted, then the rest; newest registration first within each.
- S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung CancerActive, not recruitingNCT04155034Phase 3
- Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Phase 1/2
- Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCActive, not recruitingNCT04140526Phase 1/2
- Appatinib Combined With S-1 in the Treatment of Small Cell Lung CancerStatus unknownNCT04128800Phase 2
- Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid TumorsTerminatedNCT04116320Phase 1
- Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular ImmunotherapyTerminatedNCT04106167
- Closed vs. Open Face Masks for Cranial RadiotherapyCompletedNCT04079595Not applicable
- Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung CancerStatus unknownNCT04073550Phase 3
- GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic AdenocarcinomaTerminatedNCT04060342Phase 1
- Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide ChemotherapyStatus unknownNCT04056949Phase 2
- Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer TreatmentsActive, not recruitingNCT04056247
- Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLCCompletedNCT04055792Phase 2
- A Study of SHR-1316 and Fluzoparib（SHR-3162） in Small Cell Lung Cancer PatientsCompletedNCT04041011Phase 1
- The Registry of Oncology Outcomes Associated with Testing and TreatmentCompletedNCT04028479
- A Study of Atezolizumab in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung CancerCompletedNCT04028050Phase 3
- A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)TerminatedNCT04022876Phase 1
- Toripalimab in Combination With Platinum Plus Etoposidein Patients With Extensive-Stage Small Cell Lung CancerCompletedNCT04012606Phase 3
- Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLCCompletedNCT04010357Phase 2
- A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid TumorsCompletedNCT03997968Phase 1/2
- Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLCStatus unknownNCT03994744Phase 2
- Study of Sintlimab Maintenance Therapy in Patients With Extensive Small Cell Lung CancerStatus unknownNCT03983759Phase 2
- PD-1 Inhibitors Consolidation in Extensive-stage Small Cell Lung CancerStatus unknownNCT03971214Phase 1
- A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLCTerminatedNCT03963414Phase 1
- Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung CancerActive, not recruitingNCT03923270Phase 1
- Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus ChemotherapyCompletedNCT03911219
- CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC)Status unknownNCT03904719Phase 2
- A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung CancerCompletedNCT03898791Phase 1
- The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)Status unknownNCT03896958
- Clinical Study of First-line Treatment of Small Cell Lung Cancer (SCLC) With Anlotinib HydrochlorideStatus unknownNCT03890055Phase 4
- Neoantigen-primed DC Vaccines Therapy for Refractory Lung CancerStatus unknownNCT03871205Phase 1
- A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung CancerCompletedNCT03850067Phase 1
- A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid TumorsCompletedNCT03849469Phase 1
- Anlotinib Combined With Etoposide and Platinum in the Treatment of Lung CancerStatus unknownNCT03841136Phase 2
- FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid TumorsCompletedNCT03841110Phase 1
- Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line ChemotherapyActive, not recruitingNCT03830918Phase 1/2
- S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung CancerCompletedNCT03823118Phase 2
- A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid TumorsCompletedNCT03811652Phase 1
- Toripalimab as Monotherapy for Patients With Small Cell Carcinoma of Esophagus Who Failed ChemotherapyStatus unknownNCT03811379Phase 2
- A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical PracticeCompletedNCT03782207
- Study of Anlotinib as the Maintenance Therapy for Extensive-stage Small Cell Lung CancerStatus unknownNCT03781869Phase 2
- Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLCStatus unknownNCT03780283Phase 2
- PEG-rhG-CSF in Elderly Patients With Small Cell Lung Cancer Receiving ChemotherapyStatus unknownNCT03776604Not applicable
- Maintenance Therapy for Small-cell Lung CancerCompletedNCT03769935Phase 2
- SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung CancerStatus unknownNCT03755115Phase 2
- A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)CompletedNCT03752398Phase 1
- TS Overexpression in SCLC: Mechanism and Therapeutic TargetingCompletedNCT03741829
- A Phase 1 Study of ZSP1602 in Participants With Advanced Solid TumorsStatus unknownNCT03734913Phase 1
- Anlotinib in Treatment of Recurrent Small Cell Lung CancerStatus unknownNCT03732846Phase 2
- Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine CancerCompletedNCT03728361Phase 2
- Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)Status unknownNCT03711305Phase 3
- A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLCStatus unknownNCT03700359Phase 2
- RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung CancerTerminatedNCT03699956Phase 3
- Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung CancerActive, not recruitingNCT03672773Phase 2
- Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based ChemotherapyActive, not recruitingNCT03670056Phase 2
- Methylprednisolone After Split-course Chemoradiotherapy For Bulky Local Advanced None-small Cell Lung CancerTerminatedNCT03661567Phase 2
- Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung CancerCompletedNCT03659578Phase 2
- A Safety and Tolerability Study of INCAGN02390 in Select Advanced MalignanciesCompletedNCT03652077Phase 1
- Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung CancerStatus unknownNCT03651219Phase 3
- A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung CancerCompletedNCT03639194Phase 1
- Irinotecan Plus Lobaplatin Versus Irinotecan in the Second-line Treatment of Small Cell Lung CancerStatus unknownNCT03613753Phase 2
- Etoposide Plus Lobaplatin Versus Etoposide Plus Cisplatin for Patients With Limited Small-cell Lung CancerStatus unknownNCT03613597Phase 2
- A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid TumorsCompletedNCT03595059Phase 1
- Chemoradiation With Durvalumab Followed by Durvalumab Maintenance for Limited Disease Small Cell Lung CancerStatus unknownNCT03585998Phase 2
- DOTATOC PET/CT for Imaging NET PatientsActive, not recruitingNCT03583528
- Immunotherapy in Combination With Chemotherapy in Small-cell Lung CancerCompletedNCT03568097Phase 2
- A Prospective, Single-center, One-arm Clinical Study of Apatinib Combined With Chemotherapy for Pretreated Patients With Advanced Small Cell Lung CancerCompletedNCT03547804Phase 2
- Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung CancerActive, not recruitingNCT03540420Phase 2
- A Safety and Tolerability Study of INCAGN02385 in Select Advanced MalignanciesCompletedNCT03538028Phase 1
- A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung CancerCompletedNCT03532880Phase 1
- Neoadjuvant Therapy Combined With Radical Surgery for the Treatment of Small Cell Lung Cancer (SCLC) in II and IIIA StageStatus unknownNCT03523234Not applicable
- A Study of XmAb®20717 in Subjects With Selected Advanced Solid TumorsCompletedNCT03517488Phase 1
- A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung CancerTerminatedNCT03516084Phase 3
- A Mobile Supportive Care App for Patients With Metastatic Lung CancerStatus unknownNCT03512015Not applicable
- Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid TumorsCompletedNCT03509012Phase 1
- Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Associated With Chinese Patients With Advanced Lung CancerCompletedNCT03505515
- Expanded Access to Rovalpituzumab TesirineNo longer availableNCT03503890
- Lung Cancer Screening Using DNA Methylation Changes in Circulated Tumor and PBMC DNATerminatedNCT03499678
- Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2]CompletedNCT03428607Phase 2
- Treatment Patterns in Advanced Small Cell Lung Cancer (SCLC)CompletedNCT03425825
- Transformation Into Small Cell Lung Cancer : a Mode of Resistance to TreatmentCompletedNCT03419286
- NK Cell-based Immunotherapy as Maintenance Therapy for Small-Cell Lung Cancer.Status unknownNCT03410368Phase 2
- A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLCSuspendedNCT03392064Phase 1
- Study of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung CancerStatus unknownNCT03389087Phase 2
- APG-1252 in Patients With SCLC or Advanced Solid TumorsTerminatedNCT03387332Phase 1
- Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung CancerCompletedNCT03371979Phase 1/2
- AZD 2811 Monotherapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N3]TerminatedNCT03366675Phase 2
- Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung CancerWithdrawnNCT03334487Phase 3
- Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)Active, not recruitingNCT03319940Phase 1
- A Study of PLX2853 in Advanced Malignancies.CompletedNCT03297424Phase 1
- Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung CancerStatus unknownNCT03253068Phase 2
- Next-generation Sequencing of Small Cell Lung Cancer to Identify Susceptibility Gene and to Assess TreatmentStatus unknownNCT03244904
- Bioinformation Therapy for Lung CancerCompletedNCT03239171Phase 2/3
- A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)CompletedNCT03232593
- QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsActive, not recruitingNCT03228667Phase 2
- Study in Patients With SCLC of Veliparib in Combination With TopotecanStatus unknownNCT03227016Phase 1
- Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung CancerActive, not recruitingNCT03223155Phase 1
- PEN-866 in Patients With Advanced Solid MalignanciesStatus unknownNCT03221400Phase 1/2
- Study of Nab-paclitaxel in Sensitive and Refractory Relapsed SCLCStatus unknownNCT03219762Phase 2
- A Study of MGD013 in Patients With Unresectable or Metastatic NeoplasmsCompletedNCT03219268Phase 1
- Phase Ib/II Study of Chiauranib in Patients With Small Cell Lung CancerCompletedNCT03216343Phase 1